+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure



Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure



JAMA 298(13): 1525-1532



Context Practice guidelines recommend implantable cardioverter-defibrillator (ICD) therapy for patients with heart failure and left ventricular ejection fraction of 30% or less. The influence of sex and race on ICD use among eligible patients is unknown.Objective To examine sex and racial differences in the use of ICD therapy.Design, Setting, and Patients Observational analysis of 13 034 patients admitted with heart failure and left ventricular ejection fraction of 30% or less and discharged alive from hospitals in the American Heart Association's Get With the Guidelines Heart Failure quality-improvement program. Patients were treated between January 2005 and June 2007 at 217 participating hospitals.Main Outcome Measures Use of ICD therapy or planned ICD therapy at discharge. Results Among patients eligible for ICD therapy, 4615 (35.4%) had ICD therapy at discharge (1614 with new ICDs, 527 with planned ICDs, and 2474 with prior ICDs). ICDs were used in 375 of 1329 eligible black women (28.2%), 754 of 2531 white women (29.8%), 660 of 1977 black men (33.4%), and 2356 of 5403 white men (43.6%) (P < .001). After adjustment for patient characteristics and hospital factors, the adjusted odds of ICD use were 0.73 (95% confidence interval, 0.60-0.88) for black men, 0.62 (95% confidence interval, 0.56-0.68) for white women, and 0.56 (95% confidence interval, 0.44-0.71) for black women, compared with white men. The differences were not attributable to the proportions of women and black patients at participating hospitals or to differences in the reporting of left ventricular ejection fraction.Conclusions Less than 40% of potentially eligible patients hospitalized for heart failure received ICD therapy, and rates of use were lower among eligible women and black patients than among white men.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 021741506

Download citation: RISBibTeXText

PMID: 17911497

DOI: 10.1001/jama.298.13.1525


Related references

Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure. Journal of Cardiovascular Electrophysiology 24(6): 664-671, 2013

Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. American Journal of Therapeutics 17(4): E78-E87, 2010

Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program. Circulation 134(7): 517-526, 2016

System survival of nontransvenous implantable cardioverter-defibrillators compared to transvenous implantable cardioverter-defibrillators in pediatric and congenital heart disease patients. Heart Rhythm 7(2): 193-198, 2010

Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time?. Circulation 125(9): 1094-1101, 2012

Disease-specific quality of life-patient acceptance: racial and gender differences in patients with implantable cardioverter defibrillators. Journal of Cardiovascular Nursing 28(3): 285-293, 2013

Small device may offer big boost to heart failure survival. Implantable cardioverter-defibrillators are now routinely recommended for many heart failure patients. Heart Advisor 13(3): 6-6, 2012

Remote monitoring reduces healthcare use and improves quality of care in heart failure patients with implantable defibrillators: the evolution of management strategies of heart failure patients with implantable defibrillators (EVOLVO) study. Circulation 125(24): 2985-2992, 2012

Sotalol as adjunctive therapy to implantable cardioverter-defibrillators in heart failure patients. Congestive Heart Failure 15(3): 144-147, 2010

Planning for Deactivation of Implantable Cardioverter Defibrillators at the End of Life in Patients With Heart Failure. Critical Care Nurse 36(6): 24-31, 2016

The role of implantable cardioverter-defibrillators in advanced heart failure patients awaiting orthotopic heart transplantation. Journal of the American College of Cardiology 37(2 Supplement A): 108A, February, 2001

Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure. Bmj 351(): H3529-H3529, 2015

Longitudinal study of implantable cardioverter-defibrillators: methods and clinical characteristics of patients receiving implantable cardioverter-defibrillators for primary prevention in contemporary practice. Circulation. Cardiovascular Quality and Outcomes 5(6): E78-E85, 2013

Protein biomarkers identify patients unlikely to benefit from primary prevention implantable cardioverter defibrillators: findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD). Circulation. Arrhythmia and Electrophysiology 7(6): 1084-1091, 2015

In patients with heart failure, do implantable cardioverter-defibrillators delay death or save lives?. Italian Heart Journal. Supplement 3(1): 36-44, 2002